DYN — Dyne Therapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2020-09-17.
Performance
Technicals
Others in Healthcare
Measured signals that fired on DYN
| date | signal | measured base rate |
|---|---|---|
| 2026-08-05 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-08-04 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-07-24 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-06-26 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-05-18 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-04-17 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-14 | Rhodes Jason P Director | Open-market sale 10b5-1 plan | 1.4M | 25.00 | 34.0M |
| 2026-08-14 | Rhodes Jason P Director | Open-market sale 10b5-1 plan | 478.4K | 25.00 | 12.0M |
| 2026-08-14 | Rhodes Jason P Director | Open-market sale 10b5-1 plan | 322.5K | 25.00 | 8.1M |
| 2026-08-13 | Rhodes Jason P Director | Open-market sale 10b5-1 plan | 268.4K | 26.20 | 7.0M |
| 2026-08-13 | Rhodes Jason P Director | Open-market sale 10b5-1 plan | 94.4K | 26.20 | 2.5M |
| 2026-08-13 | Rhodes Jason P Director | Open-market sale 10b5-1 plan | 63.6K | 26.20 | 1.7M |
| 2026-08-13 | Cox John CEO & President | Open-market sale 10b5-1 plan | 5.0K | 26.28 | 131.0K |
| 2026-08-13 | Lucera Erick Chief Financial Officer | Open-market sale 10b5-1 plan | 1.8K | 26.28 | 47.2K |
| 2026-08-13 | Kerr Douglas Chief Medical Officer | Open-market sale 10b5-1 plan | 1.6K | 26.28 | 40.9K |
| 2026-08-13 | Friedl-Naderer Johanna Chief Commercial Officer | Open-market sale 10b5-1 plan | 226 | 26.28 | 5.9K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| JANUS HENDERSON GROUP PLC | 247.4M | 13.6M |
| BlackRock, Inc. | 212.1M | 11.7M |
| Atlas Venture Life Science Advisors, LLC | 165.5M | 9.1M |
| FMR LLC | 161.5M | 8.9M |
| Orbis Allan Gray Ltd | 122.6M | 6.8M |
| STATE STREET CORP | 120.6M | 6.7M |
| VANGUARD CAPITAL MANAGEMENT LLC | 116.1M | 6.4M |
| PERCEPTIVE ADVISORS LLC | 84.6M | 4.7M |
| FCPM III SERVICES B.V. | 84.2M | 4.6M |
| TCG Crossover Management, LLC | 83.7M | 4.6M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Ask the AI about DYN
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →